Form 990 for tax year 2022
Filed by FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND.
Totals
- Total revenue
- $9,316,837
- Total expenses
- $1,014,874
- Contributions and grants received
- $14,920,274
- Grants paid
- $0
- Program service revenue
- $0
- Investment income
- -$5,603,437
- Other revenue
- $0
- Total assets, end of year
- $47,303,067
- Total liabilities, end of year
- $65,457
- Net assets or fund balances, end of year
- $47,237,610
- Program services expenses (Part IX)
- $973,431
- Management and general expenses
- $41,443
- Fundraising expenses
- $0
- Program service expenses (Part III)
- $973,431
Program services were 95.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1d · Related organizations
$14,920,274
-
7a · Gross sales of assets other than inventory
securities $303,672
-
7b · Less cost or other basis and sales expenses
securities $5,907,109
-
7c · Gain or loss
securities -$5,603,437
-
7d · Net gain or loss
total -$5,603,437 · excluded -$5,603,437
Functional expenses
Part IX, the statement of functional expenses.
-
5 · Compensation of officers, directors and key employees
total $674,390 · program services $674,390
-
7 · Other salaries and wages
total $28,027 · program services $28,027
-
8 · Pension plan contributions
total $33,987 · program services $33,987
-
9 · Other employee benefits
total $65,187 · program services $65,187
-
10 · Payroll taxes
total $43,867 · program services $43,867
-
11a · Fees: management
total $17,342 · program services $1,525 · management and general $15,817
-
11b · Fees: legal
total $48,523 · program services $32,224 · management and general $16,299
-
11c · Fees: accounting
total $7,823 · management and general $7,823
-
12 · Advertising and promotion
total $3,824 · program services $3,824
-
13 · Office expenses
total $6,804 · program services $6,804
-
16 · Occupancy
total $20,396 · program services $20,396
-
17 · Travel
total $27,835 · program services $27,835
-
19 · Conferences, conventions and meetings
total $26,560 · program services $26,560
-
24a · Other expenses: PRINTING & PRODUCTION
total $7,786 · program services $6,565 · management and general $1,221
-
24e · All other expenses
total $2,523 · program services $2,240 · management and general $283
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,604,228 · end of year $313,572
-
4 · Accounts receivable
beginning of year $49,510
-
7 · Other notes and loans receivable
end of year $1,965,012
-
9 · Prepaid expenses and deferred charges
beginning of year $4,417 · end of year $6,199
-
13 · Investments: program-related
beginning of year $37,103,878 · end of year $37,780,078
-
15 · Other assets
beginning of year $6,588,060 · end of year $7,238,206
-
17 · Accounts payable and accrued expenses
beginning of year $65,457 · end of year $65,457
-
25 · Other liabilities
beginning of year $351,055 · end of year $0
-
27 · Net assets without donor restrictions
beginning of year $44,933,581 · end of year $47,237,610
Mission and programs · 2022
Mission
THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND'S MISSION IS TO ACCELERATE THE TRANSLATION OF RETINAL LABORATORY-BASED RESEARCH INTO CLINICAL TRIALS TO EXPEDITE THE COMMERCIALIZATION OF PATIENT THERAPIES.
-
THE THREE LARGEST PROGRAM SERVICES ACCOMPLISHMENTS (AS MEASURED BY EXPENSES) FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND (FFB-RDF) DURING FISCAL 2023 WERE EQUITY INVESTMENTS IN OPUS GENETICS, PERCEIVE BIO, AND AMBER BIO. OPUS GENETICS AND PERCEIVE BIO ARE BOTH CLINICALLY STAGED GENE THERAPY COMPANIES, AND AMBER BIO IS A PRECLINICAL STAGE COMPANY. EACH OF THESE COMPANIES IS FOCUSED ON ADVANCING PROMISING THERAPIES FOR RETINAL DEGENERATIVE DISEASES.FISCAL 2023 SUMMARY:FFB-RDF INVESTED AN ADDITIONAL $7,000,000 IN OPUS GENETICS TO HELP ADVANCE ITS PIPELINE OF ORPHAN INHERITED RETINAL DISEASE INDICATIONS INCLUDING LCA5, BEST1, RDH12 AND MERTK. THE FIRST PATIENT WAS DOSED IN THE LCA5 PHASE I/II CLINICAL TRIAL IN AUGUST 2023. FFB-RDF INVESTED $2,564,098 IN PERCEIVE BIO TO HELP ADVANCE A CLINICAL-STAGE COMPLEMENT FACTOR H GENE THERAPY PROGRAM FOR THE TREATMENT OF DRY AMD, AND AN EARLY STAGED DUAL LEUCINE KINASE-DEPENDENT INHIBITOR PROGRAM AIMED AT AXONAL NEUROPROTECTION FOR THE TREATMENT OF GLAUCOMA AND RETINAL DISEASES.FFB-RDF INVESTED $1,800,000 IN AMBER BIO TO HELP SUPPORT THE DEVELOPMENT OF AN RNA EDITING PLATFORM THAT WILL BE FIRST APPLIED TO RETINAL DEGENERATIVE DISEASES.
Expenses $973,431
As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Mark Blumenkranz MD MmsMARK BLUMENKRANZ MD MMS
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
David BrintDAVID BRINT
EX OFFICIO DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 10 related
-
Warren ThalerWARREN THALER
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Jose-Alain Sahel MDJOSE-ALAIN SAHEL MD
DIRECTOR
- Total calculated
- $15,000
- From this org
- $0
- From related orgs
- $15,000
- Other
- $0
- Hours/week
- 1 + 1 related
-
Adrienne Graves PhDADRIENNE GRAVES PHD
CHAIRMAN
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Kelly LisbakkenKELLY LISBAKKEN
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Jacque Duncan MDJACQUE DUNCAN MD
EX OFFICIO DIRECTOR
- Total calculated
- $75,000
- From this org
- $0
- From related orgs
- $75,000
- Other
- $0
- Hours/week
- 1 + 5 related
-
Jonathan Steinberg MDJONATHAN STEINBERG MD
EX OFFICIO DIRECTOR
- Total calculated
- $0
- Hours/week
- 1 + 1 related
-
Tony Adamis MDTONY ADAMIS MD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Jean Bennett MD PhDJEAN BENNETT MD PHD
DIRECTOR
- Total calculated
- $0
- Hours/week
- 1
-
Catherine Bowes Rickman PhDCATHERINE BOWES RICKMAN PHD
DIRECTOR
- Total calculated
- $15,000
- From this org
- $0
- From related orgs
- $15,000
- Other
- $0
- Hours/week
- 1 + 1 related
-
Benjamin R YerxaBENJAMIN R YERXA
CEO (THRU 7/1/22)
- Total calculated
- $622,172
- From this org
- $133,821
- From related orgs
- $445,893
- Other
- $42,458
- Hours/week
- 14 + 26 related
Schedule J breakdown matched by us
- Base
- $101,576 + $386,010 related
- Bonus
- $32,049 + $59,520 related
- Other
- $196 + $363 related
- Deferred
- $1,540 + $2,860 related
- Nontaxable benefits
- $8,418 + $29,640 related
- Filer's total
- $143,779 + $478,393 related
-
Jason D MenzoJASON D MENZO
CEO (BEG 7/1/22)
- Total calculated
- $523,027
- From this org
- $91,780
- From related orgs
- $367,118
- Other
- $64,129
- Hours/week
- 8 + 32 related
Schedule J breakdown matched by us
- Base
- $79,826 + $319,304 related
- Bonus
- $11,879 + $47,514 related
- Other
- $75 + $300 related
- Deferred
- $3,578 + $14,312 related
- Nontaxable benefits
- $9,248 + $36,991 related
- Filer's total
- $104,606 + $418,421 related
-
Peter GinsbergPETER GINSBERG
COO
- Total calculated
- $389,133
- From this org
- $66,023
- From related orgs
- $264,095
- Other
- $59,015
- Hours/week
- 8 + 32 related
Schedule J breakdown matched by us
- Base
- $58,888 + $235,553 related
- Bonus
- $6,920 + $27,682 related
- Other
- $215 + $860 related
- Deferred
- $3,397 + $13,588 related
- Nontaxable benefits
- $8,406 + $33,624 related
- Filer's total
- $77,826 + $311,307 related
-
Russell W KelleyRUSSELL W KELLEY
MANAGING DIRECTOR, RD FUND
- Total calculated
- $339,833
- From this org
- $280,543
- From related orgs
- $0
- Other
- $59,290
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $260,777
- Bonus
- $19,209
- Other
- $557
- Deferred
- $16,971
- Nontaxable benefits
- $42,319
- Filer's total
- $339,833
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 7 · Other non-fixed payments
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 8 · Paid under the initial-contract exception
The filer's explanations (Part III)
- PART I, LINE 7
- FFB EMPLOYEES PARTICIPATE IN AN ANNUAL INCENTIVE PLAN. THE PLAN PROVIDES AN ANNUAL CASH BONUS DEPENDING UPON THE ACHIEVEMENT OF PRE-DETERMINED ORGANIZATION AND INDIVIDUAL PERFORMANCE CRITERIA.
- SCHEDULE J, PART I, LINE 3:
- THE FOUNDATION FIGHTING BLINDNESS, INC., A RELATED ORGANIZATION, ESTABLISHES THE COMPENSATION FOR THE ORGANIZATION'S EMPLOYEES. THE FOUNDATION FIGHTING BLINDNESS, INC. USES A COMPENSATION COMMITTEE, INDEPENDENT COMPENSATION CONSULTANT, 990 OF OTHER ORGANIZATIONS, A COMPENSATION SURVEY OR STUDY, AND APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE.
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
No itemized grants to organizations on this return.
Related organizations on this return
Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.
-
THE FOUNDATION FIGHTING BLINDNESS INC
501(C)(3) · RESEARCH · MD
-
MACULAR DEGENERATION INTERNATIONAL INC
501(C)(3) · FUNDRAISING · IL
Directly controlled by FOUNDATION FIGHTING BLINDNESS INC
-
NATIONAL RETINITIS PIGMENTOSA FOUNDATION
501(C)(3) · FUNDRAISING · MD
Directly controlled by FOUNDATION FIGHTING BLINDNESS INC
Taxable family on this return
Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.
Related corporations and trusts
Part IV: related organizations taxable as a corporation or trust.
-
OPUS GENETICS INC
C · GENE THERAPY · DE · 41.22% owned · share of income $34,580 · share of assets $1,981,206 · controlled entity
Directly controlled by FOUNDATION FIGHTING BLINDNESS
Provenance
- Return type
- form_990
- Tax year
- 2022
- Filed
- 1 November 2023
- IRS schema version
- 2022v5.0
- Source object
- 202303069349302335
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.